• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:31:28 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZGNX alert in real time by email
    SC 13G/A 1 d111594dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Zogenix, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    98978L 20 4

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA

     


      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Perceptive Life Sciences Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    Item 1(a).

    Name of Issuer:

    Zogenix, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    5959 Horton Street, Suite 500, Emeryville, California 94608

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    98978L 20 4

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:   Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:   Managing Member

     

    Get the next $ZGNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZGNX

    DatePrice TargetRatingAnalyst
    2/28/2022Outperform → Market Perform
    Northland Capital
    1/19/2022Buy → Hold
    Needham
    12/20/2021$37.00 → $32.00Outperform
    SVB Leerink
    9/9/2021$23.00Buy
    UBS
    8/6/2021$48.00 → $44.00Buy
    Needham
    8/6/2021$42.00 → $37.00Outperform
    SVB Leerink
    More analyst ratings

    $ZGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Smith Michael P closing all direct ownership in the company (withholding obligation)

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:19:21 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Breitmeyer James B closing all direct ownership in the company (for tax liability)

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:16:42 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stutts Mary E. to satisfy withholding obligation

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:15:11 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    SEC Filings

    See more
    • SEC Form 15-12B filed by Zogenix Inc.

      15-12B - ZOGENIX, INC. (0001375151) (Filer)

      3/17/22 8:00:59 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zogenix Inc.

      EFFECT - ZOGENIX, INC. (0001375151) (Filer)

      3/8/22 12:15:16 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zogenix Inc.

      EFFECT - ZOGENIX, INC. (0001375151) (Filer)

      3/8/22 12:15:08 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UCB Completes Acquisition of Zogenix, Inc.

      BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ:ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US $1.9 billion / €1.7 billion*. Charl van Zyl, Executive Vice President, Neurology & Head of Europe/International Markets, UCB, said: "We are very pleased to reach today's milestone at the earliest opportunity

      3/7/22 12:00:00 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

      Two podium and one poster presentation share important new findings on FINTEPLA's safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the U.S.1 EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Mee

      3/4/22 8:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

      Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

      3/1/22 11:35:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zogenix downgraded by Northland Capital

      Northland Capital downgraded Zogenix from Outperform to Market Perform

      2/28/22 1:52:35 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix downgraded by Needham

      Needham downgraded Zogenix from Buy to Hold

      1/19/22 2:38:51 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Zogenix with a new price target

      SVB Leerink reiterated coverage of Zogenix with a rating of Outperform and set a new price target of $32.00 from $37.00 previously

      12/20/21 4:55:58 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-9) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 05/30/2023. Application Category: NDA, Application Number: 212102, Application Classification: REMS

      5/31/23 12:11:20 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-6) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 01/03/2023. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

      1/4/23 12:43:03 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-5) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 06/15/2022. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

      6/16/22 4:37:19 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

      Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

      3/1/22 11:35:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/14/22 9:05:54 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/11/22 11:43:17 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/10/22 8:47:19 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Financials

    Live finance-specific insights

    See more
    • Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

      Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan's Ministry of Health, Labour & Welfare for the marketing approval of FINTEPLA in Dravet syndromePreviously announced agreement to be acquired by UCB; transaction expected to close in the first half of

      2/28/22 8:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UCB to acquire Zogenix

      BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine fo

      1/19/22 1:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results

      FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Continuing to advance late-stage development programs for FINTEPLA and MT1621 EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update. The Company will host a conferen

      11/4/21 4:05:00 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care